search
Back to results

The Involvement of ATP Sensitive Potassium Channel in Migraine Aura and Migraine Pain.

Primary Purpose

Headache, Migraine With Aura, Migraine Without Aura

Status
Recruiting
Phase
Not Applicable
Locations
Denmark
Study Type
Interventional
Intervention
Levcromakalim
Sponsored by
Danish Headache Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Headache

Eligibility Criteria

18 Years - 60 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Migraine patients
  • 18-60 years.
  • 50-100 kg.
  • Women of childbearing potential must use adequate contraception.

Exclusion Criteria:

  • A history of serious somatic disease
  • Any other type of headache (except episodic tension-type headache less than once a month) Daily intake of any medication except contraceptives Contraindications for MRI scan.

Sites / Locations

  • Danish headache centerRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Levcromakalim

placebo (isotonic saline)

Arm Description

Intravenous infusion of 1 mg levcromakalim followed by intravenous sumatriptan infusion.

Intravenous infusion of placebo (isotonic saline) followed by intravenous sumatriptan infusion.

Outcomes

Primary Outcome Measures

Dynamic diffusion weighted image (DWI)
To measure transient diffusivity changes related to levcromakalim-induced CSD during the aura phase of migraine in subjects with migraine with aura.

Secondary Outcome Measures

Vascular imaging before sumatriptan
To investigate the diameter of middle meningeal arteries (MMA), superficial temporal arteries (STA) and middle cerebral arteries (MCA) measured by millimeters (mm).
Vascular imaging after sumatriptan
To investigate the diameter of middle meningeal arteries (MMA), superficial temporal arteries (STA) and middle cerebral arteries (MCA) measured by millimeters (mm).

Full Information

First Posted
September 27, 2022
Last Updated
March 21, 2023
Sponsor
Danish Headache Center
search

1. Study Identification

Unique Protocol Identification Number
NCT05565001
Brief Title
The Involvement of ATP Sensitive Potassium Channel in Migraine Aura and Migraine Pain.
Official Title
Structural and Functional Cerebral Changes After Infusion of ATP Sensitive Potassium Channel Opener Levcromakalim.
Study Type
Interventional

2. Study Status

Record Verification Date
March 2023
Overall Recruitment Status
Recruiting
Study Start Date
September 1, 2022 (Actual)
Primary Completion Date
July 31, 2023 (Anticipated)
Study Completion Date
July 31, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Danish Headache Center

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The aim of the present study to investigate whether Opening of KATP channels causes migraine pain by activation of meningeal nociceptors and ascending trigeminal nociceptive pathways. Opening of KATP channels causes migraine aura by induction of CSD.
Detailed Description
Migraine Pain The trigeminovascular system is the anatomical and physiological substrate of migraine pain. Nociceptive transmission originates from activation and sensitization of first-order trigeminovascular neurons. Their cell bodies are in the trigeminal ganglion, and their afferent fibers innervate the meninges and its vessels. Ascending nociceptive transmission from the trigeminal ganglion is projected to the brain stem, activating and sensitizing second-order trigeminovascular neurons, including those in the spinal trigeminal nucleus. This, in turn, activates and sensitizes third-order trigeminovascular neurons in the thalamus, which subsequently relay the nociceptive transmission to the somatosensory cortex and other cortical areas, ultimately resulting in migraine pain. Although the biological underpinnings of migraine pain are incompletely understood, signaling pathways have been identified that are putatively responsible for the genesis of migraine pain. Recent human experimental data have implicated opening of KATP channels in migraine pathogenesis. In two randomized controlled trials, it was demonstrated that intravenous infusion of levcromakalim - an opener of KATP channels - induced migraine pain in people with migraine with and without aura. - It remains unknown whether KATP channel opening causes migraine pain by activation of meningeal nociceptors and ascending trigeminal nociceptive pathways, as proposed during spontaneous migraine attacks. Migraine Aura About one-third of people with migraine experience aura symptoms, which are characterized by reversible focal neurologic symptoms, typically comprising visual or hemisensory disturbances. The physiological substrate of the aura phase of migraine is thought to be cortical spreading depression (CSD), a self-propagating wave of depolarization across the cerebral cortex that disrupts ionic gradients and is followed by cerebral hypoperfusion. Recently, it was reported that intravenous infusion of levcromakalim - an opener of KATP channels - induced migraine aura in migraine with aura patients. - It remains unknown whether KATP channel opening causes CSD which leads to migraine aura, as observed during spontaneous migraine attacks.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Headache, Migraine With Aura, Migraine Without Aura

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
20 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Levcromakalim
Arm Type
Active Comparator
Arm Description
Intravenous infusion of 1 mg levcromakalim followed by intravenous sumatriptan infusion.
Arm Title
placebo (isotonic saline)
Arm Type
Placebo Comparator
Arm Description
Intravenous infusion of placebo (isotonic saline) followed by intravenous sumatriptan infusion.
Intervention Type
Drug
Intervention Name(s)
Levcromakalim
Intervention Description
Intravenous administration of levcromakalim or placebo over 20 minutes. After 3 hours from the administration of levcromakalim or placebo, participants will receive intravenous infusion of sumatriptan over 10 minutes.
Primary Outcome Measure Information:
Title
Dynamic diffusion weighted image (DWI)
Description
To measure transient diffusivity changes related to levcromakalim-induced CSD during the aura phase of migraine in subjects with migraine with aura.
Time Frame
Before and after infusion of levcromakalim compared with before and after infusion of saline. Time of measurements is baseline, 20 minutes and 160 minutes after the infusion.
Secondary Outcome Measure Information:
Title
Vascular imaging before sumatriptan
Description
To investigate the diameter of middle meningeal arteries (MMA), superficial temporal arteries (STA) and middle cerebral arteries (MCA) measured by millimeters (mm).
Time Frame
Before and after infusion of levcromakalim compared with before and after infusion of saline. Time of measurements is baseline, 20 minutes and 160 minutes after the infusion.
Title
Vascular imaging after sumatriptan
Description
To investigate the diameter of middle meningeal arteries (MMA), superficial temporal arteries (STA) and middle cerebral arteries (MCA) measured by millimeters (mm).
Time Frame
Before and after infusion of sumatriptan. Time of measurements is 200 minutes and 210 minutes after the infusion.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Migraine patients 18-60 years. 50-100 kg. Women of childbearing potential must use adequate contraception. Exclusion Criteria: A history of serious somatic disease Any other type of headache (except episodic tension-type headache less than once a month) Daily intake of any medication except contraceptives Contraindications for MRI scan.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Mohammad Al-Mahdi Al-Karagholi
Phone
00 45 31 19 16 47
Email
mahdi.alkaragholi@gmail.com
Facility Information:
Facility Name
Danish headache center
City
Copenhagen
State/Province
Glostrup
ZIP/Postal Code
2600
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mohammad Al-Mahdi A Al-Karagholi
Phone
+4531191647
Email
mahdi.alkaragholi@gmail.com

12. IPD Sharing Statement

Learn more about this trial

The Involvement of ATP Sensitive Potassium Channel in Migraine Aura and Migraine Pain.

We'll reach out to this number within 24 hrs